Top 5 global vaccine products based on revenue in 2016 and 2022 (in million U.S. dollars)

Loading statistic...
20162022
Prevnar 13 (Pfizer + Daewoong)6,0345,749
Gardasil (Merck & Co)2,4882,513
Pentacel (Sanofi)1,6542,128
Fluzone (Sanofi)1,6832,068
Bexsero (GlaxoSmithKline)5281,170
© Statista 2017

Show further information

Show sources information

AdvertisementTableau Software
 
About This Statistic

This statistic displays the top 5 global vaccine products based on their revenues worldwide in 2016, and a projection for 2022. Pfizer's pneumococcal vaccine, Prevnar 13, is expected to generate some 5.75 billion U.S. dollars in revenues by 2022. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.


Top vaccine products

Vaccines act as a preventive measure to improve immunity to certain diseases. Often, vaccines are created from a weakened or killed form of a microbe which allows the immune system to react and create a record of it, so that in the future, it can easily recognize these microorganisms. Vaccine use can easily help to prevent contraction of certain viruses such as influenza. However, some countries may not have easy access to vaccinations. In India, there were approximately 1.8 million deaths due to vaccine-preventable diseases as of 2013.

The global vaccination market generated 27.5 billion U.S. dollars in 2016 and is projected to total around 35 billion U.S. dollars in 2022. As of 2014, there were 18 new vaccines that were moving along the research and development pipeline for neglected diseases. Vaccines in the United States accumulated some of the world’s largest revenues, totaling 10.8 billion U.S. dollars in 2013. In comparison, Germany generated around three billion U.S. dollars at the vaccine market. Prevnar 13 and Gardasil are the top vaccines in the world, generating 6 billion and 2.5 billion U.S. dollars, respectively, in 2016. Prevnar 13 is marketed by Pfizer and Daewoong.

Show more
Special Functions
Download as ...
Graphic (PNG)
Excel (XLS)
PowerPoint (PPT)
PDF
Options
Settings
Print
Research Alerts
Download started
Please be patient - this may take a moment

Statista Accounts: Access All Statistics. Starting from $588 / Year

Statistics on "Influenza in the U.S."

  • Global overview
The most important statistics
  • U.S. overview
The most important statistics
  • Prevention
The most important statistics
  • Flu vaccination
The most important statistics
  • Miscellaneous

Related Studies: Available to Download in PDF or PPTX Format

Top pharmaceutical drugs

All Information
in one Presentation

Top pharmaceutical drugs

Everything On "Top pharmaceutical drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers

Statista for Your Company: The Research and Analysis Tool

  • Product Film
  • Statistics
  • Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Further Content: Statistics, Studies, and Topic Pages

Our Business Solutions: Save Time and Money

only

$588*

per year
Your advantages
  • Full access to all our statistics
  • Download as XLS, PDF & PNG
  • Relevant data: complete source information
All functions of our platform illustrated face-to-face
  • Learn how Statista supports your company
  • Extensive tour across the whole portal
  • Personal guidance by our support team
The knowledge database for your company
  • All functions of the Premium Account
  • Access to dossiers, forecasts and studies
  • Access to our international database
  • Publishing rights and other exclusive functions